New developments in surgery of malignant gliomas

Open access

New developments in surgery of malignant gliomas

Background. Malignant gliomas account for a high proportion of brain tumours. With new advances in neurooncology, the recurrence-free survival of patients with malignant gliomas has been substantially prolonged. It, however, remains dependent on the thoroughness of the surgical resection. The maximal tumour resection without additional postoperative deficit is the goal of surgery on patients with malignant gliomas. In order to minimize postoperative deficit, several pre- and intraoperative techniques have been developed.

Conclusions. Several techniques used in malignant glioma surgery have been developed, including microsurgery, neuroendoscopy, stereotactic biopsy and brachytherapy. Imaging and functional techniques allowing for safer tumour resection have a special value. Imaging techniques allow for better preoperative visualization and choice of the approach, while functional techniques help us locate eloquent regions of the brain.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Baur M Preusser M Piribauer M Elandt K Hassler M Hudec M et al. Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. Radiol Oncol 2010; 44: 113-20.

  • Velnar T Smrdel U Popovic M Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-8.

  • Sanai N Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62: 753-64.

  • Vuorinen V Hinkka S Färkkilä M Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003; 145: 5-10.

  • Žele T Matos B Knific J Bajrović FF Prestor B. Use of 3D visualisation of medical images for planning and intraoperative localisation of superficial brain tumours: our experience. Br J Neurosurg 2010; 24: 555-60.

  • Kockro RA Serra L Tseng-Tsai Y Chan C Yih-Yian S Gim-Guan C et al. Planning and simulation of neurosurgery in a virtual reality environment. Neurosurgery 2000; 46: 118-35.

  • Wadley J Dorward N Kitchen N Thomas D. Pre-operative planning and intra-operative guidance in modern neurosurgery: a review of 300 cases. Ann R Coll Surg Engl 1999; 81: 217-25.

  • Enchev Y Bozinov O Miller D Tirakotai W Heinze S Benes L et al. Imageguided ultrasonography for recurrent cystic gliomas. Acta Neurochir (Wien) 2006; 148: 1053-63.

  • Stummer W Pichlmeier U Meinel T Wiestler OD Zanella F Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.

  • Van Meir EG Hadjipanayis CG Norden AD Shu H Wen PY Olson JJ. Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-93.

  • Picht T Mularski S Kuehn B Vajkoczy P Kombos T Suess O. Navigated transcranial magnetic stimulation for preoperative functional diagnostics in brain tumor surgery. Neurosurgery 2009; 65(6 Suppl): 93-8.

  • Cappabianca P Cinalli G Gangemi M Brunori A Cavallo LM de Divitiis E et al. Application of neuroendoscopy to intraventricular lesions. Neurosurgery 2008; 62(Suppl 2): 575-97.

  • Simon M Schramm J. Surgical management of intracranial gliomas. Recent Results Cancer Res 2009; 171: 105-24.

  • Bock HC Puchner MJ Lohmann F Schütze M Koll S Ketter R et al. Firstline treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010; 33: 441-9.

  • Darakchiev BJ Albright RE Breneman JC Warnick RE. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108: 236-42.

  • La Rocca RV Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 2009; 25: 149-60.

Search
Journal information
Impact Factor


IMPACT FACTOR 2018: 1,846
5-year IMPACT FACTOR: 1,923

CiteScore 2018: 1.94

SCImago Journal Rank (SJR) 2018: 0.651
Source Normalized Impact per Paper (SNIP) 2018: 0.867


Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 115 60 3
PDF Downloads 66 54 1